The Journal of Clinical Psychiatry

Author Index to Volume 68: January 2007 Through December 2007

Abad MT see Lindenmayer J-P
Abdallah TA see Friedman S
Abel KM see Flynn SM
Abelskov K see Kørner A
Aboujaoude EN see Koran LM
Abrams K see Cosci F
Adams AS see Bambauer KZ
Adler CM see DelBello MP
Adler LA see Michelson D
Ahmed S see Keller MB; Kocsis JH
Ahmed TS see Jain U
Ahuja N. Azithromycin and catatonic symptoms [letter with reply]. Feb 336–337
Ahuja N, Lloyd AJ. Aripiprazole and worsening of psychosis: a case report [letter]. May 805–806
Aichhorn W, Stelzig-Schoeler R, Geretsegger C, Stuppaeck C, Kemmler G. Bright light therapy for negative symptoms in schizophrenia: a pilot study [letter]. July 1146
Aiello M see Robertson B
Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. Aug 1230–1236
Aizaga K see Rutherford BR
Akhtar S see Saddichha S
Akman C see Uguz F
Alaräisänen A see Riala K
Albert U see Maina G
Aldama A see González-Pinto A
Alegria M see Fortuna LR
Aleman A, Sommer IE, Kahn RS. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. Mar 416–421
Alessi-Severini S. Reply to Flynn SW: Clozapine interchangeability issues [letter]. Aug 1310–1311
Allen JJB see Schnyer RN
Alonso J, Lépine J-P. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). Suppl 2, 3–9
Alonso J see Nutt DJ
Alpert J see Yeung A
Alpert JE see Davis LL
Alvarez E see Lemoine P
Amado JA see Perez-Iglesias R
Amanbekova D see Madhusoodanan S
Amano N see Sugiyama N
Ameen S see Saddichha S
Amminger GP see Berger GE
Amsterdam JD see Clayton AH; Cusin C; Dunner DL; Michelson D
Andersson HM see Kahn RS
Andrade C see Kumar PNS
Andreasen RG. Review of Mathews M, Budur K, Basil B, Mathews M: *Psychiatry: 1200 Questions to Help You Pass the Boards.* Jan 173
Andreassen OA see Birkenaes AB
Andreescu C, Mulsant BH, Peasley-Miklus C, Rothschild AJ, Flint AJ, Heo M, Caswell M, Whyte EM, Meyers BS, for the STOP-PD Study Group. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Feb 194–200
Angst J see Stassen HH
Appleton WS. Review of Marangell LB, Martinez JM: *Concise Guide to Psychopharmacology, 2nd ed.* Nov 1817–1818
Appolinario JC see Claudino AM
Arakawa R see Dunn JA
Aripiprazole Study Group see Kane JM; Keck PE Jr
Arnold KK, Yager J. Case of unexpected and selective remission of a 20-year history of ephedrine dependence following treatment with low-dose aripiprazole [letter]. Oct 1620–1621
Arnold LE see Findling RL
Aro TA see Honkonen TI
Arranz B, San L. Reply to Karagianis J: What do we know about insulin resistance and glucose metabolism in patients with schizophrenia treated with antipsychotics? [letter] May 799–802
Arrasate M see González-Pinto A
Arvilommi P, Suominen KS, Mantere OK, Leppämäki S, Valtonen H, Isometsä ET. Adequacy of treatment received by diagnosed and undiagnosed patients with bipolar I and II disorders. Jan 102–110
Ascher-Svanum H see Dunayevich E
Ashton AK. Indexing of reports on aripiprazole augmentation of clozapine [letter with reply]. Feb 334–335
Atkinson JM, Douglas-Hall P, Fischetti C, Sparshatt A, Taylor DM. Outcome following clozapine discontinuation: a retrospective analysis. July 1027–1030
Attiullah N see Zimmerman M
Auby P see Tran-Johnson TK
Augustin H see Juckel G
Auther AM see Cornblatt BA
Bacaltchuk J see Claudino AM
Bai YM, Chen J-Y, Yang W-S, Chi Y-C, Liou Y-J, Lin C-C, Wang Y-C, Lin C-Y, Su T-P, Chou P. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. Dec 1834–1839
Bai YM, Chen TT, Chen J-Y, Chang W-H, Wu B, Hung CH, Lin WK. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. Aug 1218–1225
Bailer U see Souery D
Bajbouj M see Merkl A
Baker DG see Friedman MJ
Balan V see Martin KA
Balanza J see Huertas D
Balasubramani GK see Morris DW
Baldassano CF see Truman CJ
Baldessarini RJ see Guzzetta F; Viguera AC
Ball SG see Endicott J
Bambauer KZ, Soumerai SB, Adams AS, Zhang F, Ross-Degnan D. Provider and patient characteristics associated with antidepressant nonadherence: the impact of provider specialty. June 867–873
Barber JP see Milrod BL
Barkin J see Davis LL
Barlow DH see McHugh RK
Barnas C see Kapusta ND
Bartoli L see Maj M
Bartolucci AA see Davis LL
Bauer AD see Ghaemi SN
Bauer M see Crossley NA
Bauer MS see Kilbourne AM; Simon GE
Bauer SM see Plattner B
Bäuml J, Pitschel-Walz G, Volz A, Engel RR, Kissling W. Psychoeducation in schizophrenia: 7-year follow-up concerning rehospitalization and days in hospital in the Munich Psychosis Information Project study. June 854–861
Baup N see Gaillard R
Beach TG see Coon KD
Beasley CM Jr see Cusin C
Bebbington P see Moran P
Bechdolf A see Gaebel W
Bedotto H see Herz MI
Behere RV, Venkatasubramanian G, Naveen MN, Gangadhar BN. Aripiprazole-induced hyponatremia: a case report [letter]. Apr 640–641
Bellodi L see Maina G

Belmonte-de-Abreu P see Reinhardt MC
Benbow A. Mental illness, stigma, and the media. Suppl 2, 31–35
Benbow A see Nutt DJ
Benca RM. Narcolepsy and excessive daytime sleepiness: diagnostic considerations, epidemiology, and comorbidities. Suppl 13, 5–8
Bender DS see Skodol AE
Bender S see Gaebel W
Benetti L see Reinhardt MC
Benjamin S. Review of Miller BL, Cummings JL: *The Human Frontal Lobes: Functions and Disorders, 2nd ed.* Nov 1817
Bennett M see Van Ameringen M
Bental RP see Drake RJ
Berger GE, Proffitt T-M, McConchie M, Yuen H, Wood SJ, Amminger GP, Brewer W, McGorry PD. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. Dec 1867–1875
Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A. Efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. June 843–853
Bernabei R see Liperoti R; Onder G
Bernardina BD see Cortese S
Berner JE. Intranasal ketamine for intermittent explosive disorder: a case report [letter]. Aug 1305
Bernet W see Ray N
Bernstein IH see Moore HK
Bersudsky Y see Lerner V; Libov I
Beyer J see Robertson B
Bhakta SG see Kumar PNS
Bhat SK. American idols [A PSYCHIATRIST'S DIARY]. Mar 481–482
Bhat SK. Are you analyzing me? [A PSYCHIATRIST'S DIARY]. Nov 1809–1810
Bhat SK. Flat world psychiatry [A PSYCHIATRIST'S DIARY]. Oct 1615–1616
Bhat SK. My first day [A PSYCHIATRIST'S DIARY]. Aug 1303–1304
Bhat SK. Paranoia of prejudice [A PSYCHIATRIST'S DIARY]. June 968–969
Bhat SK. Reply to Green A: If Buddha were in treatment [letter]. July 1150
Bhat SK. Simple fools [A PSYCHIATRIST'S DIARY]. Apr 633–634
Bhat SK. Sweat [A PSYCHIATRIST'S DIARY]. Jan 165–166
Bhat SK. Where experts are many [A PSYCHIATRIST'S DIARY]. July 1144–1145
Bhugra D see Moran P
Biederman J. Reply to Kruszewski SP: Modafinil: mischaracterization [letter]. June 970–972
Biederman J see Monuteaux MC; Surman CBH
Binstock AB see Miller KK
Birkeland KI see Birkenaes AB
Birkenaes AB, Opjordsmoen S, Brunborg C, Engh JA, Jonsdottir H, Ringen PA, Simonsen C, Vaskinn A, Birkeland KI, Friis S, Sundet K, Andreassen OA. Level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. June 917–923
Blanch J see Plana MT
Blaustein ME see van der Kolk BA
Bleau P see Katzman MA
Blier P, Keller MB, Pollack MH, Thase ME, Zajecka JM, Dunner DL. Preventing recurrent depression: long-term treatment for major depressive disorder. Mar e06
Bloch MH see Coric V
Boerescu D see Zimmerman M
Bogetto F see Maina G
Bollen J see Souery D
Borba CP see Henderson DC
Bossie CA see Gharabawi GM
Bottas A see McIntyre RS
Bowden CL. Reply to Feifel D: Dosing of divalproex extended release [letter]. July 1146–1147
Bowers MB see Lim S
Brakemeier EL see Merkl A
Brandes M see Pearson KH
Brashear HR, Spivey JM. Galantamine and QTc prolongation [letter with reply]. Jan 169–170
Brecher M, Leong RW, Stening G, Osterling-Koskinen L, Jones AM. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. Apr 597–603
Brecher M see Kahn RS; Sweitzer DE
Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiah D, Raskin J, Petit C, Demyttenaere K. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. Nov 1707–1716
Brenner R see Madhusoodanan S
Breteler MHM see Mol AJJ
Brewer W see Berger GE
Brodersen A-M see Kørner A
Brody AL see Grand RBG
Brophy MH. Different mechanism to understand activation/sedation side effects of ziprasidone [letter with reply]. June 974–976
Brown WA see Khan A
Brugha T see Moran P
Brunborg C see Birkenaes AB
Bryden L see Coon KD
Bucciarelli A see Leon AC
Buch S, Wagner M. Successful use of phenelzine in treatment-resistant panic disorder [letter]. Feb 335–336
Buchanan RW see Moore TA; Nelson MW
Buchkremer G see Gaebel W
Buckley PF. Introduction: the art and science of switching antipsychotic medications. Suppl 6, 4
Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. Suppl 6, 5–9
Buckley PF see Moore TA; Weiden PJ
Burgess PM see Wade D
Busch R see Hamann J; Leucht S
Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. Nov 1682–1690
Busto G see Tundo A
Cabassa LJ see Torres LR; Zayas LH
Cabral SB see Rosa MO
Cagliero E see Henderson DC
Cairney J see Schaffer A
Calabrese JR see Duax JM; Findling RL; Keck PE Jr
Caley CF see Goethe JW
Campbell BJ see Clayton AH
Campbell EC see Caroff SN
Canino G see Fortuna LR
Cao LY see Zhang XY
Capece JA see Tucker P
Carlson BX see Keck PE Jr
Carney CE, Segal ZV, Edinger JD, Krystal AD. Comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. Feb 254–260
Caroff SN, Walker P, Campbell EC, Lorry A, Petro C, Lynch K, Gallop R. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. Mar 410–415
Carpenter D see Weiden PJ
Carson WH see Berman RM; Keck PE Jr; L'Italien GJ
Carson WH Jr see Kane JM
Case M see Thase ME
Casey DE see L'Italien GJ
Cassano GB see Maina G
Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. Oct 1540–1545
Castel S see McIntyre RS
Caswell M see Andreescu C
Cath DC see de Jonge JL
Cavazos-Rehg PA see Zayas LH
Centorrino F see Guzzetta F
Chambers AS see Schnyer RN
Chamorro L see Huertas D
Chan H-Y, Lin W-W, Lin S-K, Hwang T-J, Su T-PT, Chiang S-C, Hwu H-G. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. Jan 29–36
Chan YH see Sim K

Chanen AM, Jovev M, Jackson HJ. Adaptive functioning and psychiatric symptoms in adolescents with borderline personality disorder. Feb 297–306
Chang W-H see Bai YM
Chelminski I see Zimmerman M
Chen C-Y see Cheng ATA
Chen J-Y see Bai YM
Chen L-C see Cheng ATA
Chen THH see Cheng ATA
Chen TT see Bai YM
Chen Y-S see Lin Ching-Hua
Cheng ATA, Hawton K, Chen THH, Yen AMF, Chen C-Y, Chen L-C, Teng P-R. Influence of media coverage of a celebrity suicide on subsequent suicide attempts. June 862–866
Cheng J see Markowitz JC
Cheung A see Schaffer A
Chi Y-C see Bai YM
Chiang S-C see Chan H-Y
Chiles C. Review of Rosenbaum JF, Arana GW, Hyman SE, Labbate LA, Fava M: *Handbook of Psychiatric Drug Therapy, 5th ed.* Feb 339
Chiles JA see Moore TA
Choi S-H see Yoo HK
Chokka P see Van Ameringen M
Chokka PR see Katzman MA
Chong SA see Sim K
Chou L-S see Lin Ching-Hua
Chou P see Bai YM
Chou SP see Pickering RP
Church TS see Otto MW
Cilli AS see Uguz F
Cipriani MC see Onder G
Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. Dec 1876–1885
Citrome L. Effectiveness criterion: balancing efficacy against the risks of weight gain. Suppl 12, 12–17
Citrome L. Introduction. Weighing the evidence: weight management insights for treating major mental illness. Suppl 12, 4
Citrome L. Psychopharmacology of violence with emphasis on schizophrenia, part 1: acute treatment [ASCP Corner]. Jan 163–164
Citrome L. Psychopharmacology of violence with emphasis on schizophrenia, part 2: long-term treatment [ASCP Corner]. Feb 331–332
Clara I see Cox BJ
Clark CP. Review of Watson NF, Vaughn BV (eds): *Clinician's Guide to Sleep Disorders.* Sept 1450
Clary CM see Harvey AT
Claudino AM, de Oliveira IR, Appolinario JC, Cordás TA, Duchesne M, Sichieri R, Bacaltchuk J. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. Sept 1324–1332
Clayton AH, Campbell BJ, Favit A, Yang Y, Moonsammy G, Piontek CM, Amsterdam JD. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale. Dec 1860–1866
Clayton AH see Dunn JA; Trivedi MH
Cohen D. Applicability of the oral glucose tolerance test in assessing prevalence and incidence of diabetes mellitus in schizophrenia [letter with reply]. Aug 1307–1309
Cohen L see Gaillard R
Cohen LS. Treatment of bipolar disorder during pregnancy. Suppl 9, 4–9
Cohen LS see Joffe H; Pearson KH
Cohen M see Potkin SG
Cohen R see Hamann J
Coid JW see Moran P
Colom F see Romero S
Colombo C see Maina G
Compton MT, Whicker NE, Hochman KM. Alcohol and cannabis use in urban, African American, first-episode schizophrenia-spectrum patients: associations with positive and negative symptoms. Dec 1939–1945
Compton WM see Pickering RP
Conley RR see Moore TA
Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Walker DG, Ravid R, Heward CB, Rogers J, Papassotiropoulos A, Reiman EM, Hardy J, Stephan DA. High-density whole-genome association study reveals that *APOE* is the major susceptibility gene for sporadic late-onset Alzheimer's disease. Apr 613–618
Cooper D, Moisan J, Grégoire J-P. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. June 818–825
Copeland PM see Henderson DC
Cordás TA see Claudino AM
Corey-Lisle PK see Berman RM
Coric V, Kelmendi B, Pittenger C, Wasylink S, Bloch MH, Green J. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania [letter]. Jan 170–171
Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, Lesser ML, Tai JY, Shah MR, Foley CA, Kane JM, Correll CU. Can antidepressants be used to treat the schizophrenia prodrome? results of a prospective, naturalistic treatment study of adolescents. Apr 546–557
Correa HH see Neves FS
Correll CU. Clinical psychopharmacology of pediatric mood stabilizer and antipsychotic treatment, part 1: challenges and developments [ASCP Corner]. Aug 1301–1302
Correll CU. Clinical psychopharmacology of pediatric mood stabilizer and antipsychotic treatment, part 2: methodological considerations [ASCP Corner]. Sept 1441–1442
Correll CU see Cornblatt BA
Cortese S, Isnard P, Bernardina BD, Mouren M-C. Attention-deficit/hyperactivity disorder, binge eating, and obesity [letter with reply]. June 976–977
Corya SA see Thase ME
Cosci F, Schruers KRJ, Abrams K, Griez EJL. Alcohol use disorders and panic disorder: a review of the evidence of a direct relationship. June 874–880
Courtecuisse C see Brecht S
Cox BJ, Sareen J, Enns MW, Clara I, Grant BF. Fundamental structure of Axis II personality disorders assessed in the National Epidemiologic Survey on Alcohol and Related Conditions. Dec 1913–1920
Craft LL see Otto MW
Craig DW see Coon KD
Crandall DT see Marder SR; Sachs GS
Crespo-Facorro B see Perez-Iglesias R
Crismon ML see Moore TA
Croenlein J see Brecht S
Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. June 935–940
Cruz N see Romero S
Cukor J see Difede J
Cuni L see Madhusoodanan S
Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM Jr, Rosenbaum JF, Perlis RH. Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications. Jan 52–57
Czekalla J see Karow A
Dahl M-L see Melkersson KI
Danker-Hopfe H see Merkl A
Darke AC see Jain U
Dattilo PB, Nordin C. Prolonged QT associated with an overdose of trazodone [letter]. Aug 1309–1310
Daversa MT see Skodol AE
Davidson JRT. History of the concept of atypical depression. Suppl 3, 10–15
Davidson JRT, Thase ME. History of the concept of atypical depression. [illegible]eb e03
Davis LL, Frazier EC, Gaynes BN, Trivedi MH, Wisniewski SR, Fava M, Barkin J, Kashner TM, Shelton RC, Alpert JE, Rush AJ. Are depressed outpatients with and without a family history of substance use disorder different? a baseline analysis of the STAR*D cohort. Dec 1931–1938

Davis LL, Li X, Bartolucci AA, Williford RB, Lowe JS. Pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex. Oct 1546–1551
de Bruijn C, Denys D. Predicting pharmacotherapy outcome from a retrospective chart study? [letter with reply] Jan 167–168
De Hert M see van Winkel R
de Jonge JL, Cath DC, van Balkom AJLM. Quetiapine in patients with Tourette's disorder: an open-label, flexible-dose study [letter]. July 1148–1150
De Koninck J see Lamarche LJ
de Leon J see Gelenberg AJ
de Oliveira IR see Claudino AM
Debieuvre C see Brecht S
Deforce D see Denys D
Degner D see Gaebel W
DelBello MP. "An ounce of prevention is worth a pound of cure." May 766
DelBello MP. Are girls and boys from different planets? Oct 1563–1564
DelBello MP. Can research inform the clinical care of mental health disorders in children and adolescents? Feb 296
DelBello MP. Phenomenology and assessment of childhood and adolescent mental health: progress in research. Sept 1418
DelBello MP. To medicate or not to medicate? July 1087
DelBello MP, Adler CM, Whitsel RM, Stanford KE, Strakowski SM. 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. May 789–795
Dellva MA see Dunayevich E
DeMartinis NA, Yeung PP, Entsuah R, Manley AL. Double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. May 677–688
Demeter CA see Findling RL
Demosthenous M see Marano CM
Demyttenaere K see Brecht S; Souery D
Dennehy EB see Truman CJ
Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HGM. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. May 747–753
Denys D see de Bruijn C
Depp CA see Palmer BW
Desaiah D see Brecht S
Desan PH see Pittenger C
DeSouza CM see Othmer E
Detke MJ see Endicott J
Dettling M see Körtner K
Diaz MT see Robertson B
Difede J, Cukor J, Jayasinghe N, Patt I, Jedel S, Spielman L, Giosan C, Hoffman HG. Virtual reality exposure therapy for the treatment of posttraumatic stress disorder following September 11, 2001. Nov 1639–1647
Di Spigno D see Tundo A
Dittmann RW see Karow A
Docherty JP see Weiden PJ
Donnelly GAE see Jain U
Donovan AL, Freudenreich O. Resolution of late-onset hypomania after repair of carotid artery stenosis: a case of vascular hypomania [letter]. May 798
Doraiswamy PM see Robertson B
Dossett EC, Land AJ, Gitlin MJ, Frye MA. Lack of mania prophylaxis associated with lamotrigine monotherapy in manic-predominant bipolar I disorder [letter]. June 973–974
Douglas-Hall P see Atkinson JM
Drake RJ, Dunn G, Tarrier N, Bentall RP, Haddock G, Lewis SW. Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. Jan 81–86
Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. Suppl 3, 40–44
Druss BG, Newcomer JW. Challenges and solutions to integrating mental and physical health care. Apr e09
Duax JM, Youngstrom EA, Calabrese JR, Findling RL. Sex differences in pediatric bipolar disorder. Oct 1565–1573
Dubé S see Thase ME
Duchesne M see Claudino AM
Duggal HS, Mendhekar DN. Case report of reemergence of antipsychotic-induced dyskinesia with citalopram [letter]. May 803
Duggal HS, Mendhekar DN. Reply to Ashton AK: Indexing of reports on aripiprazole augmentation of clozapine [letter]. Feb 334–335
Dunayevich E, Ascher-Svanum H, Zhao F, Jacobson JG, Phillips GA, Dellva MA, Green AI. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. Aug 1163–1171
Dunn G see Drake RJ
Dunn JA, Arakawa R, Greist JH, Clayton AH. Assessing the onset of antidepressant-induced sexual dysfunction using interactive voice response technology. Apr 525–532
Dunn LB see Palmer BW
Dunn RT see Ghaemi SN
Dunner DL. Review of Mondimore FM: *Bipolar Disorder: A Guide for Patients and Families, 2nd ed.* Sept 1449–1450
Dunner DL. Review of Mondimore FM: *Depression: The Mood Disease, 3rd ed.* Sept 1449–1450
Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. July 1071–1077. Correction, Sept 1448
Dunner DL see Blier P; Keller MB; Kocsis JH; Michelson D; Whitmyer VG
Dwolatzky T see Libov I
Ebert D see Philipsen A
Edinger JD see Carney CE
Eickhoff M see Gaebel W
Elam LC. Review of Citron K, Brouillette M-J, Beckett A (eds): *HIV and Psychiatry: A Training and Resource Manual, 2nd ed.* Apr 642
Élie R see Sepehry AA
Elkis H see Rosa MO
Ellis SP see Nakagawa A
Emslie GJ see Moore HK
Endicott J, Russell JM, Raskin J, Detke MJ, Erickson J, Ball SG, Marciniak M, Swindle RW. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. Apr 518–524
Engel RR see Bäuml J
Engelhart LM see Harvey PD
Engh JA see Birkenaes AB
Enns MW see Cox BJ
Entsuah R see DeMartinis NA; Ferguson JM; Liebowitz MR
Erickson J see Endicott J
Esposito D. Comment on "Lithium and clozapine rechallenge: a retrospective case analysis" [letter with reply]. Apr 635
Essex MJ see Infante M
Essock SM see Moore TA
Eudicone JM see Keck PE Jr; Miller DD
Evins AE see Gelenberg AJ
Eyler LT see Palmer BW
Fabbri S, Fava GA, Rafanelli C, Tomba E. Family intervention approach to loss of clinical effect during long-term antidepressant treatment: a pilot study. Sept 1348–1351
Fahnestock PA see Weiden PJ
Falcini R see Tundo A
Falkai P see Gaebel W
Fallgatter AJ see Zierhut KC
Fan X see Henderson DC
Faraone SV, Upadhyaya HP. Effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion. Nov e28

Faraone SV, Wilens TE. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. Suppl 11, 15–22
Faraone SV see Monuteaux MC; Reinhardt MC
Faravelli C see Maina G
Farfel GM see Friedman MJ
Fava GA see Fabbri S
Fava M. Augmenting antidepressants with folate: a clinical perspective. Suppl 10, 4–7
Fava M see Cusin C; Davis LL; Morris DW; Papakostas GI; Yeung A
Favaro A, Ferrara S, Santonastaso P. Reply to Plener PL: Response to self-injurious behaviors in a community sample of young women [letter]. Nov 1811–1812
Favaro A, Ferrara S, Santonastaso P. Self-injurious behavior in a community sample of young women: relationship with childhood abuse and other types of self-damaging behaviors. Jan 122–131
Favit A see Clayton AH
Fazel S, Sjöstedt G, Långström N, Grann M. Severe mental illness and risk of sexual offending in men: a case-control study based on Swedish national registers. Apr 588–596
Feifel D. Dosing of divalproex extended release [letter with reply]. July 1146–1147
Feldman JJ see Salzman C
Feng G-Y see Xu M-Q
Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. Jan 58–68
Ferguson JM see Keller MB; Kocsis JH
Ferrara S see Favaro A
Feucht M see Plattner B
Filkowski MM see Ghaemi SN
Filteau MJ see Katzman MA
Findling RL. Review of Mash EJ, Barkley RA (eds): *Treatment of Childhood Disorders, 3rd ed.* Oct 1623–1624
Findling RL, Arnold LE, Greenhill LL, Kratochvil CJ, McGough JJ. Diagnosing and managing complicated ADHD [commentary]. Dec 1963–1970
Findling RL, Frazier TW, Youngstrom EA, McNamara NK, Stansbrey RJ, Gracious BL, Reed MD, Demeter CA, Calabrese JR. Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. May 781–788
Findling RL see Duax JM
Fink M see Rasmussen KG
Finnerty M see Moore TA
Fiorillo A see Maj M
Fireman M see Matthews AM
Fischer P see Kapusta ND
Fischetti C see Atkinson JM
Fishman PA, Stang PE, Hogue SL. Impact of comorbid attention deficit disorder on the direct medical costs of treating adults with depression in managed care. Feb 248–253
Fleck J see Ghaemi SN
Flint AJ see Andreescu C
Flynn SM, Shaw JJ, Abel KM. Homicide of infants: a cross-sectional study. Oct 1501–1509
Flynn SW. Clozapine interchangeability issues [letter with reply]. Aug 1310–1311
Foley CA see Cornblatt BA
Fortuna LR, Perez DJ, Canino G, Sribney W, Alegria M. Prevalence and correlates of lifetime suicidal ideation and suicide attempts among Latino subgroups in the United States. Apr 572–581
Foust MS see Gadde KM
Francione-Witt C see Zimmerman M
Frank E see Trivedi MH
Frazier EC see Davis LL
Frazier TW see Findling RL
Freeman MP. Early career psychiatrists section [editorial]. Nov 1638
Freeman MP. Early careers and new data. Nov 1775
Freeman MP. New data inform the risk/benefit analysis in antenatal depression. Aug 1277–1278
Freeman MP. Refining the questions in women's mental health. Jan 120–121
Freeman MP. Screening and treatment for women with mood disorders associated with reproductive events. Dec 1946
Freeman MP. Sex hormones and the female brain: the toll of variability and deficiency. June 941–942
Freeman MP, Gelenberg AJ. Call for papers from early career psychiatrists [editorial]. May 653
Freeman MP see Gelenberg AJ
Freudenreich O see Donovan AL; Henderson DC
Friedman ES see Keller MB; Kocsis JH
Friedman JH see Liperoti R
Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. May 711–720
Friedman S, Abdallah TA, Oumaya M, Rouillon F, Guelfi J-D. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder [letter]. June 972–973
Friedrich MH see Plattner B
Friis S see Birkenaes AB
Frodl T see Juckel G
Frye MA see Dossett EC
Fukuda M see Yamamoto K
Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. Nov 1691–1700
Gadde KM, Yonish GM, Foust MS, Wagner HR II. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. Aug 1226–1229
Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn K-U, Lemke M, Bechdolf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller H-J, for the German Study Group on First-Episode Schizophrenia. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. Nov 1763–1774
Gaillard R, Hemras A, Habert M-O, Baup N, Naccache L, Gallarda T, Cohen L, Olié J-P. Cognitive facilitation and behavioral disinhibition with benzodiazepine: a case report [letter]. Aug 1305–1306
Galea S see Leon AC
Gallarda T see Gaillard R
Gallop R see Caroff SN
Gambassi G see Liperoti R
Gamel NN see Koran LM
Gangadhar BN see Behere RV; Rao NP
Ganguli R. Behavioral therapy for weight loss in patients with schizophrenia. Suppl 3, 19–25
Ganguli R, Vreeland B, Newcomer JW. Monitoring and managing weight gain in the mentally ill. June e14
Gao J-J see Xu M-Q
Garcia-Unzueta MT see Perez-Iglesias R
Gardner NC. Clinician's view of the data on bipolar disorder. Nov e27
Gardner T, Kosten T. Dual dependency on cocaine and alcohol in opiate addicts: treatment options [ASCP Corner]. July 1142–1143
Gattaz WF see Rosa MO
Gaulin BD see Sachs GS
Gaynes BN see Davis LL
Gelenberg AJ. New Year's thanks. Jan 6–10
Gelenberg AJ. Twenty years at the helm [editorial]. July 989–990

Gelenberg AJ, de Leon J, Evins AE, Parks JJ, Rigotti NA. Smoking cessation in patients with psychiatric disorders [commentary]. Sept 1404–1410
Gelenberg AJ, Freeman MP. Art (and blood sport) of psychopharmacology research: who has a dog in the fight? [editorial] Feb 185
Gelenberg AJ, Freeman MP. Reply to Preda A: Sponsored clinical trials and bias [letter]. Oct 1621–1622
Gelenberg AJ see Freeman MP; Keller MB; Kocsis JH
Geller B see Tillman R
George T see Grand RBG
Geralts DS see Moore HK
Geretsegger C see Aichhorn W
German Study Group on First-Episode Schizophrenia see Gaebel W
Gersing K see Robertson B
Gersons BPR see Van der Velden PG
Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, Kemp DE, Kelley ME, Bauer AD, Fleck J, Filkowski MM, Stan VA, Dunn RT. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. Dec 1840–1844
Ghaemi SN see Truman CJ; Wingo AP
Gharabawi GM, Bossie CA, Pandina GJ, Kujawa MJ, Greenspan AJ, Zhu Y. Discussion of 2 double-blind studies comparing risperidone and quetiapine in patients with schizophrenia [letter with reply]. Feb 333–334
Gharabawi GM see Harvey PD
Gibbons RD see Nakagawa A
Gill SS see Seitz DP
Giller E see Loebel AD
Gilmer WS see Ghaemi SN
Giosan C see Difede J
Gitlin MJ see Dossett EC
Goethe JW, Szarek BL, Caley CF, Woolley SB. Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review. Jan 22–28
Goff DC. Integrating general health care in private community psychiatry practice. Suppl 3, 49–54
Goff DC, Newcomer JW. Integrating general health care in private community psychiatry practice. July e19
Goff DC see Henderson DC
Gold M. Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. Mar 430–438
Goldberg JF. What constitutes evidence-based pharmacotherapy for bipolar disorder? part I: first-line treatments [ASCP Corner]. Dec 1982–1983
Goldberg JF, McElroy SL. Bipolar mixed episodes: characteristics and comorbidities. Oct e25
Goldberg JF see Ghaemi SN; Truman CJ
Goldberg P see Wilson ST
González C see González-Pinto A
Gonzales JS see Whitmyer VG
Gonzalez-Blanch C see Perez-Iglesias R
González-Pinto A, Aldama A, González C, Mosquera F, Arrasate M, Vieta E. Predictors of suicide in first-episode affective and nonaffective psychotic inpatients: five-year follow-up of patients from a catchment area in Vitoria, Spain. Feb 242–247
Goodkin K see Singh D
Goodman WK, Lydiard RB. Recognition and treatment of obsessive-compulsive disorder. Dec e30
Gorgels WJMJ see Mol AJJ
Gorman JM see McHugh RK
Gottlieb JD see Granholm E
Gottshcall H see Joffe H
Gracious BL see Findling RL
Graf E see Milrod BL
Grand RBG, Hwang S, Han J, George T, Brody AL. Short-term naturalistic treatment outcomes in cigarette smokers with substance abuse and/or mental illness. June 892–898
Granholm E, McQuaid JR, McClure FS, Link PC, Perivoliotis D, Gottlieb JD, Patterson TL, Jeste DV. Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up. May 730–737
Grann M see Fazel S
Grant BF see Cox BJ; Pickering RP
Grant JE, Kim SW. Clinical characteristics and psychiatric comorbidity of pyromania. Nov 1717–1722
Grant JE, Odlaug BL, Kim SW. Lamotrigine treatment of pathologic skin picking: an open-label study. Sept 1384–1391
Grant JE, Williams KA, Potenza MN. Impulse-control disorders in adolescent psychiatric inpatients: co-occurring disorders and sex differences. Oct 1584–1592
Grawe RW see Morken G
Green A. If Buddha were in treatment [letter with reply]. July 1150
Green AI see Dunayevich E
Green J see Coric V
Greenhill LL see Findling RL
Greenspan AJ see Gharabawi GM
Greer TL see Otto MW
Grégoire J-P see Cooper D
Greist JH see Dunn JA; Moore HK; Whitmyer VG
Grevet EH see Reinhardt MC
Grievink L see Van der Velden PG
Griez EJL see Cosci F
Griffin ML see Manwani SG
Grilo CM, Pagano ME, Skodol AE, Sanislow CA, McGlashan TH, Gunderson JG, Stout RL. Natural course of bulimia nervosa and of eating disorder not otherwise specified: 5-year prospective study of remissions, relapses, and the effects of personality disorder psychopathology [CME]. May 738–746
Grilo CM see Markowitz JC; Skodol AE
Grizenko N see Gruber R
Group for the Study of Resistant Depression (GSRD) see Souery D
Gruber R, Grizenko N, Joober R. Delayed sleep phase syndrome, ADHD, and bright light therapy [letter]. Feb 337–338
Grunebaum MF see Nakagawa A
Guelfi J-D see Friedman S
Guerdjikova A see McElroy SL
Guilleminault C see Lemoine P
Gulmann NC see Kørner A
Gunderson JG see Grilo CM; Markowitz JC; Skodol AE
Gunes A see Melkersson KI
Guo T-W see Xu M-Q
Gutierrez-Esteinou R see Marder SR; Sachs GS
Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. Mar 380–383
Habert M-O see Gaillard R
Haddock G see Drake RJ
Häfner H see Gaebel W
Haile CN see Zhang XY
Hakko H see Riala K
Hall JE see Joffe H
Hall SB see Othmer E
Halperin RF see Coon KD
Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Shared decision making and long-term outcome in schizophrenia treatment. July 992–997
Han J see Grand RBG
Hardy J see Coon KD
Härkänen T see Suvisaari JM
Harrigan S see Wade D
Harrington DT see Zimmerman M
Harrison NL. Mechanisms of sleep induction by $GABA_A$ receptor agonists. Suppl 5, 6–12
Harriss L see Hawton K
Harsanyi Z see Jain U
Harvey AT, Silkey BS, Kornstein SG, Clary CM. Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status. June 951–958
Harvey PD. Managing cognitive deficits and functioning in patients with schizophrenia. Sept e21

Harvey PD, Hassman H, Mao L, Gharabawi GM, Mahmoud RA, Engelhart LM. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. Aug 1186–1194
Hassman H see Harvey PD
Haupt DW, Kane JM. Metabolic risks and effects of atypical antipsychotic treatment. Oct e24
Hauser P see Matthews AM
Hawton K, Harriss L. Deliberate self-harm in young people: characteristics and subsequent mortality in a 20-year cohort of patients presenting to hospital. Oct 1574–1583
Hawton K see Cheng ATA
Hayashi K see Kaneita Y
He G see Xu M-Q
He L see Xu M-Q
Hechtman L see Jain U
Heeren TJ see Kok RM
Hegerl U see Juckel G
Hell D see Stassen HH
Heller VL see Pearson KH
Hemras A see Gaillard R
Henderson DC. Reply to Karagianis J: What do we know about insulin resistance and glucose metabolism in patients with schizophrenia treated with antipsychotics? [letter] May 799–802
Henderson DC. Weight gain with atypical antipsychotics: evidence and insights. Suppl 12, 18–26
Henderson DC, Cagliero E, Copeland PM, Louie PM, Borba CP, Fan X, Freudenreich O, Goff DC. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. Apr 533–541
Henley DB see Thase ME
Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. Suppl 3, 4–7
Hennekens CH see Newcomer JW
Hennen J see Manwani SG; Pearson KH
Heo M see Andreescu C
Herz MI, Bedotto H. Review of Bellack AS, Mueser KT, Gingerich S, Agresta J: *Social Skills Training for Schizophrenia: A Step-by-Step Guide, 2nd ed.* May 807–808
Herzog DB see Miller KK
Hesslinger B see Philipsen A
Hettema JM, Ross DE. Case of aripiprazole-related tardive akathisia and its treatment with ropinirole [letter]. Nov 1814–1815
Heward CB see Coon KD
Hiekkanen H see Korkeila J
Hirschfeld RMA see Keller MB; Kocsis JH
Hitt SK see Schnyer RN
Hochman KM see Compton MT
Hoffman HG see Difede J
Hoffmann VP see Karagianis J
Hogue SL see Fishman PA
Holzer L see Sofia-Gabrion CK
Hong J-P see Yoo HK
Honkonen TI, Aro TA, Isometsä ET, Virtanen EM, Katila HO. Quality of treatment and disability compensation in depression: comparison of 2 nationally representative samples with a 10-year interval in Finland. Dec 1886–1893
Hopper EK see van der Kolk BA
Hopper JW see van der Kolk BA
Hornillos M see Huertas D
Horrigan JP see Moore HK
Howard LM, Kirkwood G, Latinovic R. Sudden infant death syndrome and maternal depression. Aug 1279–1283
Howes OD, Wheeler MJ, Pilowsky LS, Landau S, Murray RM, Smith S. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. Mar 361–367
Hsu C-Y see Lin Ching-Hua
Hsu H-B see Huang C-L
Huang C-L, Su K-P, Hsu H-B, Pariante CM. Pilot observational crossover study of QTc interval changes associated with switching between olanzapine and risperidone [letter]. May 803–805
Hudson JI see McElroy SL
Huertas D, López-Ibor Aliño JJ, Molina JD, Chamorro L, Balanza J, Jiménez MP, Hornillos M. Antiaggressive effect of cyproterone versus haloperidol in Alzheimer's disease: a randomized double-blind pilot study. Mar 439–444
Hughes CW see Moore HK
Hung CH see Bai YM
Hunter EE see Othmer E
Husain MM see Rasmussen KG
Hwang S see Grand RBG
Hwang T-J see Chan H-Y
Hwu H-G see Chan H-Y
Infante M, Slattery MJ, Klein MH, Essex MJ. Association of internalizing disorders and allergies in a child and adolescent psychiatry clinical sample. Sept 1419–1425
Iosif A-M see Romero S
Irwin MR see Meeks TW
Iskander A see Lindenmayer J-P
Isnard P see Cortese S
Isometsä ET see Arvilommi P; Honkonen TI
Jackson HJ see Chanen AM
Jacobson JG see Dunayevich E
Jagadheesan K see Lusicic A
Jäger M see Gaebel W
Jain R see Manning JS; Skale TG
Jain S see Moore HK; Morris DW
Jain U, Hechtman L, Weiss M, Ahmed TS, Reiz JL, Donnelly GAE, Harsanyi Z, Darke AC. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. Feb 268–277
Jayasinghe N see Difede J
Jedel S see Difede J
Jenkins R see Moran P
Jeste DV see Granholm E; Meeks TW; Palmer BW
Jibson MD. Psychopharmacology in the emergency room [ASCP Corner]. May 796–797
Jiménez MP see Huertas D
Jockers-Scherübl MC see Gaebel W
Joffe H. Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder. Suppl 9, 10–15
Joffe H, Petrillo LF, Viguera AC, Gottshcall H, Soares CN, Hall JE, Cohen LS. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. Dec 1954–1962
Joffe H, Soares CN, Petrillo LF, Viguera AC, Somley BL, Koch JK, Cohen LS. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. June 943–950
Johnston D see Van Ameringen M
Jones AM see Brecher M
Jonsdottir H see Birkenaes AB
Joober R see Gruber R
Joseph DI. Review of Blazer DG: *The Age of Melancholy: Major Depression and Its Social Origins*. Mar 490
Jovev M see Chanen AM
Juckel G, Pogarell O, Augustin H, Mulert C, Müller-Siecheneder F, Frodl T, Mavrogiorgou P, Hegerl U. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder. Aug 1206–1212
Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, Andersson HM, Meulien D, on behalf of the Study 132 Investigators. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. June 832–842
Kahn RS see Aleman A
Kaleem M see Coon KD

Kallert TW, Priebe S, McCabe R, Kiejna A, Rymaszewska J, Nawka P, Očvár L, Raboch J, Stárková-Kališová L, Koch R, Schützwohl M. Are day hospitals effective for acutely ill psychiatric patients? a European multicenter randomized controlled trial. Feb 278–287
Kamath P, Reddy YCJ, Kandavel T. Suicidal behavior in obsessive-compulsive disorder. Nov 1741–1750
Kan CC see Mol AJJ
Kan HJ see L'Italien GJ
Kanaan RA. Reply to Esposito D: Comment on "Lithium and clozapine rechallenge: a retrospective case analysis" [letter]. Apr 635
Kanda H see Kaneita Y
Kandavel T see Kamath P; Reddy YCJ
Kane JM. Teaching and practicing psychopharmacology [ASCP CORNER]. Nov 1807–1808
Kane JM. Treatment strategies to prevent relapse and encourage remission. Suppl 14, 27–30
Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R, for the Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. Feb 213–223
Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R. Reply to Rosenheck RA: Aripiprazole and perphenazine: no difference [letter]. Nov 1812–1814
Kane JM see Cornblatt BA; Haupt DW; Leucht S
Kaneita Y, Ohida T, Osaki Y, Tanihata T, Minowa M, Suzuki K, Wada K, Kanda H, Hayashi K. Association between mental health status and sleep status among adolescents in Japan: a nationwide cross-sectional survey. Sept 1426–1435
Kaptsan A, Odessky A, Osher Y, Levine J. Lack of efficacy of 5 grams daily of creatine in schizophrenia: a randomized, double-blind, placebo-controlled trial. June 881–884
Kaptsan A see Lerner V
Kapusta ND, Mossaheb N, Barnas C, Fischer P. Aripiprazole-induced psychosis: a case report of reexposure by stepwise up-titration [letter]. Sept 1445–1446
Karagianis J, Hoffmann VP, Stauffer VL, Treuer T. What do we know about insulin resistance and glucose metabolism in patients with schizophrenia treated with antipsychotics? [letter with replies] May 799–802
Karow A, Czekalla J, Dittmann RW, Schacht A, Wagner T, Lambert M, Schimmelmann BG, Naber D. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. Jan 75–80
Kashima H see Nakagawa A
Kashner TM see Davis LL
Kasper S see Souery D
Katila HO see Honkonen TI
Katz JR see Papakostas GI
Katzman MA, Tricco AC, McIntosh D, Filteau MJ, Bleau P, Chokka PR, Kjernisted KD, Mok H, Pham B. Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. Dec 1845–1859
Kaya N see Uguz F
Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R, for the Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. Oct 1480–1491
Keck PE Jr see McElroy SL
Keefe RSE. Cognitive deficits in patients with schizophrenia: effects and treatment. Suppl 14, 8–13
Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RMA, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT. Prevention of Recurrent Episodes of depression with Venlafaxine for Two years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. Aug 1246–1256
Keller MB see Blier P; Kocsis JH
Kelley ME see Ghaemi SN
Kellner CH see Rasmussen KG
Kelmendi B see Coric V
Kelsey DK see Michelson D
Kemmler G see Aichhorn W
Kemp DE see Ghaemi SN
Kennedy SH see McIntyre RS
Kessler RC. Global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. Suppl 2, 10–19
Kessler RC see Nutt DJ
Kettl P. Helping families with end-of-life care in Alzheimer's disease. Mar 445–450
Khan A, Schwartz K, Stern C, Redding N, Kolts RL, Brown WA, Robinson DS. Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials. Dec 1828–1833
Khan A see Berman RM; Ferguson JM; Lindenmayer J-P
Khan AY see Morris DW
Khanna S see Loebel AD
Kiejna A see Kallert TW
Kilbourne AM, Valenstein M, Bauer MS. Research-to-practice gap in mood disorders: a role for the U.S. Department of Veterans Affairs [commentary]. Apr 502–504
Kim C-Y see Yoo HK
Kim E see Miller DD
Kim J-J see Pae C-U
Kim SW see Grant JE
Kindler J see Plattner B
Kinrys G, Worthington JJ, Wygant L, Nery F, Reese H, Pollack MH. Levetiracetam as adjunctive therapy for refractory anxiety disorders. July 1010–1013
Kirkwood G see Howard LM
Kissling W see Bäuml J; Hamann J; Leucht S
Kjeldgaard KM see Kørner A
Kjernisted K see Van Ameringen M
Kjernisted KD see Katzman MA
Kleber RJ see Van der Velden PG
Klein MH see Infante M
Klibanski A see Miller KK
Klimke A see Gaebel W
Klingberg S see Gaebel W
Klotz SG see Kruszewski SP
Knapp RG see Rasmussen KG
Knegtering R see Wunderink L
Koch JK see Joffe H
Koch R see Kallert TW
Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RMA, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT, Keller MB. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study. July 1014–1023
Kocsis JH see Keller MB
Kok RM, Vink D, Heeren TJ, Nolen WA. Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial. Aug 1177–1185
Kokaliari E see Plener PL
Kolts RL see Khan A
Konarski JZ see McIntyre RS
Köpcke W see Gaebel W
Koran LM, Aboujaoude EN, Gamel NN. Duloxetine treatment of dysthymia and double depression: an open-label trial. May 761–765

Koran LM, Aboujaoude EN, Gamel NN. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. Mar 422–427
Korkeila J, Salminen JK, Hiekkanen H, Salokangas RKR. Use of antidepressants and suicide rate in Finland: an ecological study. Apr 505–511
Korn DL see van der Kolk BA
Kørner A, Lauritzen L, Abelskov K, Gulmann NC, Brodersen A-M, Wedervang-Jensen T, Kjeldgaard KM. Rating scales for depression in the elderly: external and internal validity. Mar 384–389
Kornstein SG see Harvey AT; Keller MB; Kocsis JH; Whitmyer VG
Körtner K, Neuhaus AH, Schürer F, Dettling M. Eosinophilia indicating subclinical clozapine-induced pericarditis [letter]. July 1147–1148
Kosten T see Gardner T
Kosten TA see Zhang XY
Kosten TR see Zhang XY
Kotwal R see McElroy SL
Koukopoulos A see Viguera AC
Kraemer HC see Plattner B
Krahn LE see Martin KA
Krakow BJ. Physiologic sleep disorders among treatment-responsive depressed patients with residual cognitive and physical symptoms [letter]. Sept 1444–1445
Kratochvil CJ see Findling RL
Krishen A see Papakostas GI
Krishnan KR. Revisiting monoamine oxidase inhibitors. Suppl 8, 35–41
Kruszewski SP, Klotz SG. Modafinil: mischaracterization [letter with reply]. June 970–972
Krystal AD see Carney CE
Kühn K-U see Gaebel W
Kujawa MJ see Gharabawi GM
Kumar PNS, Andrade C, Bhakta SG, Singh NM. Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. Feb 237–241
Lake KA see McElroy SL
Lamarche LJ, De Koninck J. Sleep disturbance in adults with posttraumatic stress disorder: a review [CME]. Aug 1257–1270
Lambert M see Karow A
Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. Suppl 6, 10–13
Lambert TJ see Weiden PJ
Lamberti JS see Spurling RD
Land AJ see Dossett EC
Landau S see Howes OD
Landi F see Onder G
Lane H-Y see Lin Ching-Hua
Långström N see Fazel S
Lapane KL see Liperoti R
Latinovic R see Howard LM
Lau GS see Marder SR
Lauritzen L see Kørner A
Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Comparison of selected risk factors for unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia from a Danish population-based cohort. Nov 1673–1681
Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. June 899–907
Laursen TM see Munk-Olsen T
Lawson EA see Miller KK
Lazarus A see Sweitzer DE
Lecrubier Y. Widespread underrecognition and undertreatment of anxiety and mood disorders: results from 3 European studies. Suppl 2, 36–41
Lecrubier Y see Nutt DJ; Souery D
Lee C see Pae C-U
Lee C-U see Pae C-U
Lee MA. Review of McKenna PJ, Oh TM: *Schizophrenic Speech: Making Sense of Bathroots and Ponds That Fall in Doorways*. Jan 173–174
Lee S-J see Pae C-U
Lemke M see Gaebel W
Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. Nov 1723–1732
Lencz T see Cornblatt BA
Leon AC. Revised black box warning for antidepressants sets a public health experiment in motion [commentary]. July 1139–1141
Leon AC, Marzuk PM, Tardiff K, Bucciarelli A, Stajic M, Piper TM, Galea S. Antidepressants in adult suicides in New York City: 2001–2004. Sept 1399–1403
Leon AC see Milrod BL
Leonard BE see Bushe CJ
Leong RW see Brecher M
Lépine J-P see Alonso J; Nutt DJ
Leppämäki S see Arvilommi P
Lerner V, Miodownik C, Kaptsan A, Bersudsky Y, Libov I, Sela B-A, Witztum E. Vitamin B_6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. Nov 1648–1654
Lerner V see Libov I
Lesage A see McGirr A
Lesser ML see Cornblatt BA
Leucht S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. Mar 352–360
Leucht S see Hamann J
Leung D see Coon KD
Levin FR. Diagnosing attention-deficit/hyperactivity disorder in patients with substance use disorders. Suppl 11, 9–14
Levin FR, Upadhyaya HP. Diagnosing ADHD in adults with substance use disorder: DSM-IV criteria and differential diagnosis. July e18
Levine J see Kaptsan A
Levitt A see Schaffer A
Lewis SW see Drake RJ
Li S see Xu M-Q
Li X see Davis LL
Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. July 1031–1037
Libov I see Lerner V
Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety, and cost outcomes of CATIE and other trials. Feb e04
Lieberman JA see Newcomer JW; Rosenheck RA
Liebowitz MR, Yeung PP, Entsuah R. Randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. Nov 1663–1672
Liew E see Mahendran R
Lim S, Bowers MB. Augmentation of clozapine treatment with aripiprazole [letter]. May 798–799
Lin C-C see Bai YM
Lin Chieh-Hsin see Lin Ching-Hua
Lin Ching-Hua, Chou L-S, Lin Chieh-Hsin, Hsu C-Y, Chen Y-S, Lane H-Y. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. Oct 1522–1527
Lin C-Y see Bai YM
Lin P-Y, Su K-P. Meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. July 1056–1061. Correction, Sept 1448
Lin S-K see Chan H-Y
Lin WK see Bai YM
Lin W-W see Chan H-Y
Lince DH see Coon KD
Lindenmayer J-P, Khan A, Iskander A, Abad MT, Parker B. Randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. Mar 368–379

Link PC see Granholm E
Liou Y-J see Bai YM
Liperoti R, Onder G, Lapane KL, Mor V, Friedman JH, Bernabei R, Gambassi G. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. June 929–934
Liperoti R see Onder G
L'Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. Oct 1510–1516
Lloyd AJ see Ahuja N
Loebel A see Dunner DL
Loebel AD, Khanna S, Rajadhyaksha S, Siu CO, Giller E, Potkin SG. Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study. Sept 1333–1338
Lomax JW. Review of Gay P: *Freud: A Life for Our Time*. Dec 1991
Lönnqvist J see Suvisaari JM
López-Ibor Aliño JJ see Huertas D
Lorry A see Caroff SN
Louie PM see Henderson DC
Lowe JS see Davis LL
Ludman EJ see Simon GE
Lusicic A, Jagadheesan K. Sertraline versus venlafaxine XR in major depressive disorder [letter with reply]. Oct 1618–1619
Lydiard RB. Recognition and treatment of panic disorder. Nov e26
Lydiard RB. Worried sick: antidepressants, stress, and inflammation [ASCP Corner]. Oct 1613–1614
Lydiard RB see Goodman WK
Lynch K see Caroff SN
Ma Y see Yeung A
Macleod L see Moore HK
Madhusoodanan S, Cuni L, Brenner R, Sajatovic M, Palekar N, Amanbekova D. Chronic leukocytosis associated with clozapine: a case series [letter]. Mar 484–488
Magliano L see Maj M
Mago R, Monti D. Antiadrenergic treatment of antidepressant-induced excessive sweating in 3 patients [letter]. Apr 639–640
Mahendran R, Liew E, Subramaniam M. De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in Asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study. Apr 542–545
Mahmoud RA see Harvey PD
Maier W see Gaebel W
Maina G, Albert U, Bellodi L, Colombo C, Faravelli C, Monteleone P, Bogetto F, Cassano GB, Maj M. Health-related quality of life in euthymic bipolar disorder patients: differences between bipolar I and II subtypes. Feb 207–212
Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L. Phenomenology and prognostic significance of delusions in major depressive disorder: a 10-year prospective follow-up study. Sept 1411–1417
Maj M see Maina G
Maletic V. What clinicians need to know about neuroprotective issues in bipolar disorder. Dec e29
Mallinckrodt CH see Whitmyer VG
Manber R see Schnyer RN
Mancini C see Van Ameringen M
Mangano R see Ferguson JM
Manjunatha N see Saddichha S
Manley AL see DeMartinis NA
Mann JJ see Nakagawa A; Wilson ST
Manning JS, Jain R. Importance of a correct initial diagnosis and stabilization to avoid social and economic consequences. Sept e22
Mantere OK see Arvilommi P
Manwani SG, Szilagyi KA, Zablotsky B, Hennen J, Griffin ML, Weiss RD. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. Aug 1172–1176
Mao L see Harvey PD
Marano CM, Phatak P, Vemulapalli UR, Sasan A, Nalbandyan MR, Ramanujam S, Soekadar S, Demosthenous M, Regenold WT. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. Apr 512–517
Marchant BK see Reimherr FW
Marciniak M see Endicott J
Marcolin MA see Rosa MO
Marcus RN see Berman RM; Kane JM; Keck PE Jr; L'Italien GJ; Marder SR; Sachs GS; Tran-Johnson TK
Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, Gutierrez-Esteinou R, Crandall DT. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. May 662–668
Marder SR see Moore TA; Pierre JM
Markowitz JC, Skodol AE, Petkova E, Cheng J, Sanislow CA, Grilo CM, Gunderson JG, McGlashan TH. Longitudinal effects of personality disorders on psychosocial functioning of patients with major depressive disorder. Feb 186–193
Markowitz JC see Milrod BL
Marlowe L see Coon KD
Marmar CR see Friedman MJ
Martin KA, Krahn LE, Balan V, Rosati MJ. Selective serotonin reuptake inhibitors in the context of hepatitis C infection: reexamining the risks of bleeding. July 1024–1026
Martínez-Arán A see Mur M
Martinez-Garcia O see Perez-Iglesias R
Marzuk PM see Leon AC
Masand PS see Pae C-U
Massat I see Souery D
Mattes JA. More on placebo response [letter with reply]. Dec 1984–1985
Matthews AM. Review of Rothbaum BO (ed): *Pathological Anxiety: Emotional Processing in Etiology and Treatment*. May 807
Matthews AM, Fireman M, Hauser P. Lamotrigine-associated Stevens-Johnson syndrome after discontinuation of interferon, ribavirin, and filgrastim [letter]. Apr 637–639
Mavrogiorgou P see Juckel G
McCabe R see Kallert TW
McCall WV. Quality of life among patients with depression [letter]. Jan 168–169
McCarthy G see Robertson B
McClure FS see Granholm E
McConchie M see Berger GE
McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. Mar 390–398
McElroy SL see Goldberg JF; McIntyre RS
McEvoy JP. Costs of schizophrenia. Suppl 14, 4–7
McEvoy JP see Moore TA
McGirr A, Paris J, Lesage A, Renaud J, Turecki G. Risk factors for suicide completion in borderline personality disorder: a case-control study of cluster B comorbidity and impulsive aggression. May 721–729
McGlashan TH see Grilo CM; Markowitz JC; Skodol AE
McGorry PD see Berger GE; Wade D
McGough JJ see Findling RL
McHugh RK, Otto MW, Barlow DH, Gorman JM, Shear MK, Woods SW. Cost-efficacy of individual and combined treatments for panic disorder. July 1038–1044
McIntosh D see Katzman MA
McIntyre RS, McElroy SL, Konarski JZ, Soczynska JK, Bottas A, Castel S, Wilkins K, Kennedy SH. Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. Sept 1352–1357
McIntyre RS see Keck PE Jr
McNamara NK see Findling RL
McQuade RD see Berman RM; Kane JM; Keck PE Jr; Sachs GS; Tran-Johnson TK
McQuaid JR see Granholm E

Mechanic D. Barriers to help-seeking, detection, and adequate treatment for anxiety and mood disorders: implications for health care policy. Suppl 2, 20–26
Mechanic D see Nutt DJ
Meeks TW, Wetherell JL, Irwin MR, Redwine LS, Jeste DV. Complementary and alternative treatments for late-life depression, anxiety, and sleep disturbance: a review of randomized controlled trials. Oct 1461–1471
Meenaghan EM see Miller KK
Melkersson KI, Scordo MG, Gunes A, Dahl M-L. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. May 697–704
Meltzer HY see Kane JM
Mendelson WB. Combining pharmacologic and nonpharmacologic therapies for insomnia. Suppl 5, 19–23
Mendhekar DN see Duggal HS
Mendlewicz J see Souery D
Merkl A, Brakemeier EL, Danker-Hopfe H, Bajbouj M. Vagus nerve stimulation improves restless legs syndrome associated with major depression: a case report [letter]. Apr 635–636
Mestas R see Reimherr FW
Meulien D see Kahn RS
Meyer JM. Antipsychotic safety and efficacy concerns. Suppl 14, 20–26
Meyer JM. Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial. Suppl 1, 28–33
Meyers AL see Whitmyer VG
Meyers BS see Andreescu C
Michelson D, Adler LA, Amsterdam JD, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF, Kelsey DK, Williams DW. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. Apr 582–587
Miller AL see Moore TA; Weiden PJ
Miller DD, Eudicone JM, Pikalov A, Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. Dec 1901–1906
Miller DD see Moore TA
Miller KK, Wexler TL, Zha AM, Lawson EA, Meenaghan EM, Misra M, Binstock AB, Herzog DB, Klibanski A. Androgen deficiency: association with increased anxiety and depression symptom severity in anorexia nervosa. June 959–965
Milrod BL, Leon AC, Barber JP, Markowitz JC, Graf E. Do comorbid personality disorders moderate panic-focused psychotherapy? an exploratory examination of the American Psychiatric Association Practice Guideline. June 885–891
Minowa M see Kaneita Y
Miodownik C see Lerner V; Libov I
Mischoulon D, Raab MF. Role of folate in depression and dementia. Suppl 10, 28–33
Mischoulon D see Yeung A
Misra M see Miller KK
Miyaoka H see Yamamoto K
Moisan J see Cooper D
Mok H see Katzman MA
Mol AJJ, Voshaar RCO, Gorgels WJMJ, Breteler MHM, van Balkom AJLM, van de Lisdonk EH, Kan CC, Zitman FG. Role of craving in relapse after discontinuation of long-term benzodiazepine use. Dec 1894–1900
Molina JD see Huertas D
Möller H-J see Gaebel W
Monteleone P see Maina G
Montgomery S see Souery D
Montgomery SA see Papakostas GI
Monti D see Mago R
Monuteaux MC, Spencer TJ, Faraone SV, Wilson AM, Biederman J. Randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder. July 1094–1101
Moonsammy G see Clayton AH
Moore HK, Hughes CW, Mundt JC, Rush AJ, Macleod L, Emslie GJ, Jain S, Geralts DS, Bernstein IH, Horrigan JP, Trivedi MH, Greist JH. Pilot study of an electronic, adolescent version of the Quick Inventory of Depressive Symptomatology. Sept 1436–1440
Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL. Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. Nov 1751–1762
Mor V see Liperoti R
Moran P, Stewart R, Brugha T, Bebbington P, Bhugra D, Jenkins R, Coid JW. Personality disorder and cardiovascular disease: results from a national household survey. Jan 69–74
Moreno FA see Schnyer RN
Morenz BM. Review of Wright JH, Basco MR, Thase ME: *Learning Cognitive-Behavior Therapy: an Illustrated Guide*. Feb 342
Morken G, Grawe RW, Widen JH. Effects of integrated treatment on antipsychotic medication adherence in a randomized trial in recent-onset schizophrenia. Apr 566–571
Morris DW, Rush AJ, Jain S, Fava M, Wisniewski SR, Balasubramani GK, Khan AY, Trivedi MH. Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression study data. Sept 1339–1347
Mors O see Munk-Olsen T
Mortensen PB see Laursen TM; Munk-Olsen T
Mosquera F see González-Pinto A
Mossaheb N see Kapusta ND
Mouren M-C see Cortese S
Mueller M see Rasmussen KG
Mukundan S Jr see Robertson B
Mulert C see Juckel G
Müller-Siecheneder F see Juckel G
Mulsant BH see Andreescu C
Mundt JC see Moore HK
Munk-Olsen T, Laursen TM, Pedersen CB, Mors O, Mortensen PB. Family and partner psychopathology and the risk of postpartum mental disorders. Dec 1947–1953
Munk-Olsen T see Laursen TM
Mur M, Portella MJ, Martínez-Arán A, Pifarré J, Vieta E. Persistent neuropsychological deficit in euthymic bipolar patients: executive function as a core deficit. July 1078–1086
Murray RM see Howes OD
Musgnung J see Keller MB; Kocsis JH
Muzina DJ see Viguera AC
Myczkowski M see Rosa MO
Myers AJ see Coon KD
Naber D see Karow A
Naccache L see Gaillard R
Nakagawa A, Grunebaum MF, Ellis SP, Oquendo MA, Kashima H, Gibbons RD, Mann JJ. Association of suicide and antidepressant prescription rates in Japan, 1999–2003. June 908–916
Nakamura-Palacios EM see Furieri FA
Nakayama E see Cornblatt BA
Nalbandyan MR see Marano CM
Nash JL. Review of Reich H: *The First and Final Nightmare of Sonia Reich: A Son's Memoir*. July 1152
Nasrallah HA. Introduction. Evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond. Suppl 1, 3–4
Nasrallah HA. Roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. Suppl 1, 5–11
Naveen MN see Behere RV
Nawka P see Kallert TW

Nelson EB see McElroy SL
Nelson MW, Buchanan RW. Reply to Brashear HR: Galantamine and QTc prolongation [letter]. Jan 169–170
Nelson SH. Review of Thornicroft G: *Shunned: Discrimination Against People With Mental Illness*. Dec 1990–1991
Nemeroff CB. Prevalence and management of treatment-resistant depression. Suppl 8, 17–25
Nemeroff CB see Keller MB; Kocsis JH
Nery F see Kinrys G
Neuhaus AH see Körtner K
Neves FS, Correa HH. Is smoking associated with suicide in bipolar patients? [letter with reply] Sept 1446–1448
Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. Suppl 3, 8–13
Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. Suppl 1, 20–27
Newcomer JW, Hennekens CH. Series introduction and cardiovascular disease in patients with schizophrenia. May e12
Newcomer JW, Lieberman JA. Comparing safety and tolerability of antipsychotic treatment. Mar e07
Newcomer JW, Sernyak MJ. Identifying metabolic risks with antipsychotics and monitoring and management strategies. July e17
Newcomer JW see Druss BG; Ganguli R; Goff DC; Parks JJ; Weiden PJ
Nickel EJ see Othmer E
Nickel MK. Aripiprazole treatment of patients with borderline personality disorder [letter]. Nov 1815–1816
Nienhuis FJ see Wunderink L
Nierenberg AA see Michelson D; Ostacher MJ
Ninan PT see Keller MB; Kocsis JH
Nishino S. Narcolepsy: pathophysiology and pharmacology. Suppl 13, 9–15
Nogawa A see Yamamoto K
Nolen WA see Kok RM
Nonacs RM see Pearson KH
Nordentoft M see Laursen TM
Nordin C see Dattilo PB
Nurcombe B. Review of Rutter M: *Genes and Behavior: Nature-Nurture Interplay Explained*. July 1151
Nutt DJ, Kessler RC, Alonso J, Benbow A, Lecrubier Y, Lépine J-P, Mechanic D, Tylee A. Consensus statement on the benefit to the community of ESEMeD (European Study of the Epidemiology of Mental Disorders) survey data on depression and anxiety. Suppl 2, 42–48
Oakman J see Van Ameringen M
O'Connor MK see Rasmussen KG
Očvár L see Kallert TW
Odessky A see Kaptsan A
Odlaug BL see Grant JE
Ohida T see Kaneita Y
Ohmann C see Gaebel W
Olff M see Van der Velden PG
Olié J-P see Gaillard R
Olsen D see Spurling RD
Olsen R see Cornblatt BA
Onder G, Liperoti R, Soldato M, Cipriani MC, Bernabei R, Landi F. Depression and risk of nursing home admission among older adults in home care in Europe: results from the Aged in Home Care (AdHOC) study [CME]. Sept 1392–1398
Onder G see Liperoti R
Operskalski BH see Simon GE
Opjordsmoen S see Birkenaes AB
Oquendo MA see Nakagawa A; Wilson ST
Oren DA see Tran-Johnson TK
Osaki Y see Kaneita Y
Osher Y see Kaptsan A
Ostacher MJ, Perlis RH, Nierenberg AA. Reply to Neves FS: Is smoking associated with suicide in bipolar patients? [letter] Sept 1446–1448
Osterling-Koskinen L see Brecher M
Osuntokun O see Thase ME
Oswald P see Souery D
Othmer E, DeSouza CM, Penick EC, Nickel EJ, Hunter EE, Othmer SC, Powell BJ, Hall SB. Indicators of mania in depressed outpatients: a retrospective analysis of data from the Kansas 1500 study. Jan 47–51
Othmer SC see Othmer E
Otto MW, Church TS, Craft LL, Greer TL, Smits JAJ, Trivedi MH. Exercise for mood and anxiety disorders [commentary]. May 669–676
Otto MW see McHugh RK
Oumaya M see Friedman S
Pacchiaroti I see Romero S
Pae C-U, Kim J-J, Lee C-U, Lee S-J, Lee C, Patkar AA, Masand PS, Paik I-H. Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial. Mar 399–405
Pagano ME see Grilo CM; Skodol AE
Paik I-H see Pae C-U
Palazov VD see Kahn RS
Palekar N see Madhusoodanan S
Palmer BW, Dunn LB, Depp CA, Eyler LT, Jeste DV. Decisional capacity to consent to research among patients with bipolar disorder: comparison with schizophrenia patients and healthy subjects. May 689–696
Panagides J see Potkin SG
Pandina GJ see Gharabawi GM
Papakostas GI. Limitations of contemporary antidepressants: tolerability. Suppl 10, 11–17
Papakostas GI, Montgomery SA, Thase ME, Katz JR, Krishen A, Tucker VL. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials. Dec 1907–1912
Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. June 826–831
Papassotiropoulos A see Coon KD
Pariante CM see Huang C-L
Paris J see McGirr A
Park S see Yoo HK
Parker B see Lindenmayer J-P
Parker GB. Atypical depression: a valid subtype? Suppl 3, 18–22
Parker GB, Thase ME. Atypical depression: a valid subtype? Mar e08
Parks JJ. Implementing practice guidelines: lessons from public mental health settings. Suppl 3, 45–48
Parks JJ, Newcomer JW. Implementing evidence-based medicine: lessons from public mental health settings. June e16
Parks JJ see Gelenberg AJ
Patkar AA see Pae C-U
Patt I see Difede J
Patterson B see Van Ameringen M
Patterson TL see Granholm E
Pearson JV see Coon KD
Pearson KH, Nonacs RM, Viguera AC, Heller VL, Petrillo LF, Brandes M, Hennen J, Cohen LS. Birth outcomes following prenatal exposure to antidepressants. Aug 1284–1289
Peasley-Miklus C see Andreescu C
Pedersen CB see Munk-Olsen T
Pedersen RD see Keller MB; Kocsis JH
Peloian JH see Pierre JM
Penick EC see Othmer E
Perälä J see Suvisaari JM
Perez DJ see Fortuna LR
Pérez MC see Torres LR; Zayas LH
Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. Nov 1733–1740
Perivoliotis D see Granholm E
Perlis RH see Cusin C; Ostacher MJ
Perlov E see Philipsen A
Petit C see Brecht S
Petkova E see Markowitz JC
Petrides G see Rasmussen KG
Petrillo LF see Joffe H; Pearson KH
Petro C see Caroff SN
Pham B see Katzman MA
Phatak P see Marano CM
Philipsen A, van Elst LT, Perlov E, Ebert D, Hesslinger B. Corpus callosum dysplasia in adult attention-deficit/hyperactivity disorder: a case report [letter]. Dec 1985–1988

Phillips GA see Dunayevich E
Pickering RP, Grant BF, Chou SP, Compton WM. Are overweight, obesity, and extreme obesity associated with psychopathology? results from the National Epidemiologic Survey on Alcohol and Related Conditions. July 998–1009
Pierre JM, Peloian JH, Wirshing DA, Wirshing WC, Marder SR. Randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. May 705–710
Pifarré J see Mur M
Pikalov A see Marder SR; Miller DD
Pikalov A III see Sachs GS
Pilowsky LS see Howes OD
Piontek CM see Clayton AH
Piper TM see Leon AC
Pirozzi R see Maj M
Pitschel-Walz G see Bäuml J
Pittenger C, Desan PH. Gabapentin abuse, and delirium tremens upon gabapentin withdrawal [letter]. Mar 483–484
Pittenger C see Coric V
Plana MT, Blanch J. Reply to Ahuja N: Azithromycin and catatonic symptoms [letter]. Feb 336–337
Plattner B, The SSL, Kraemer HC, Williams RP, Bauer SM, Kindler J, Feucht M, Friedrich MH, Steiner H. Suicidality, psychopathology, and gender in incarcerated adolescents in Austria. Oct 1593–1600
Plener PL, Kokaliari E. Response to self-injurious behaviors in a community sample of young women [letter with reply]. Nov 1811–1812
Pogarell O see Juckel G
Pohl D see Zimmerman M
Pollack MH see Blier P; Kinrys G
Portella MJ see Mur M
Potenza MN see Grant JE
Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. Oct 1492–1500
Potkin SG see Loebel AD
Potvin S see Sepehry AA
Powell BJ see Othmer E
Preda A. Sponsored clinical trials and bias [letter with reply]. Oct 1621–1622
Preskorn SH see Weiden PJ
Preven DW. Review of Gold JH (ed): *Psychotherapy Supervision and Consultation in Clinical Practice*. Oct 1623
Priebe S see Kallert TW
Proffitt T-M see Berger GE
Pultz JA see Marder SR; Sachs GS
Quitkin FM see Cusin C
Raab MF see Mischoulon D
Raboch J see Kallert TW
Rafanelli C see Fabbri S
Rajadhyaksha S see Loebel AD
Ramanujam S see Marano CM
Ramirez-Bonilla ML see Perez-Iglesias R
Randall ET see Surman CBH
Rao NP, Venkatasubramanian G, Gangadhar BN. Treatment of cognitive deficits in schizophrenia with atomoxetine: a case report [letter]. Dec 1988–1989
Rapaport MH. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art. Suppl 8, 41–46
Rapaport MH. Translating the evidence on atypical depression into clinical practice. Suppl 3, 31–36
Rapaport MH, Thase ME. Translating the evidence on atypical depression into clinical practice. Apr e11
Räsänen P see Riala K
Rasgon NL see Vemuri MP
Raskin J see Brecht S; Endicott J
Rasmussen KG, Mueller M, Knapp RG, Husain MM, Rummans TA, Sampson SM, O'Connor MK, Petrides G, Fink M, Kellner CH. Antidepressant medication treatment failure does not predict lower remission with ECT for major depressive disorder: a report from the Consortium for Research in Electroconvulsive Therapy. Nov 1701–1706
Ravid R see Coon KD
Ray N, Bernet W. Review of Simon RI, Shuman DW: *Clinical Manual of Psychiatry and Law*. Sept 1449
Redding N see Khan A
Reddy YCJ, Kandavel T. Reply to de Bruijn C: Predicting pharmacotherapy outcome from a retrospective chart study? [letter] Jan 167–168
Reddy YCJ see Kamath P
Redwine LS see Meeks TW
Reed MD see Findling RL
Reese H see Kinrys G
Regenold WT see Marano CM
Reiman EM. Clinical trials and tribulations. Mar 428–429
Reiman EM. In this issue: entering the era of high-density genome-wide association studies. Apr 611–612
Reiman EM see Coon KD; Tariot PN
Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK. Double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. Jan 93–101
Reimherr FW see Cusin C; Michelson D
Reinhardt MC, Benetti L, Victor MM, Grevet EH, Belmonte-de-Abreu P, Faraone SV, Rohde LA. Is age-at-onset criterion relevant for the response to methylphenidate in attention-deficit/hyperactivity disorder? July 1109–1116
Reiz JL see Jain U
Renaud J see McGirr A
Renner TJ see Zierhut KC
Reunanen A see Suvisaari JM
Reyes EB see Kahn RS
Riala K, Alaräisänen A, Taanila A, Hakko H, Timonen M, Räsänen P. Regular daily smoking among 14-year-old adolescents increases the subsequent risk for suicide: the Northern Finland 1966 Birth Cohort Study. May 775–780
Richter MM see Zierhut KC
Riesbeck M see Gaebel W
Rigonatti SP see Rosa MO
Rigotti NA see Gelenberg AJ
Ringen PA see Birkenaes AB
Roberts MW. Review of Greenspan SI, Wieder S: *Infant and Early Childhood Mental Health: A Comprehensive Developmental Approach to Assessment and Intervention*. Feb 340–341
Robertson B, Wang L, Diaz MT, Aiello M, Gersing K, Beyer J, Mukundan S Jr, McCarthy G, Doraiswamy PM. Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. Feb 261–267
Robinson DG see Moore TA
Robinson DS see Khan A
Rofman ES. Review of Gillig PM, McQuistion HL (eds): *Clinical Guide to the Treatment of the Mentally Ill Homeless Person*. June 979
Rogers J see Coon KD
Rohde LA see Reinhardt MC
Romano SJ see Dunner DL
Romero S, Colom F, Iosif A-M, Cruz N, Pacchiaroti I, Sanchez-Moreno J, Vieta E. Relevance of family history of suicide in the long-term outcome of bipolar disorders. Oct 1517–1521
Ronis RJ. Review of Reddy R, Keshavan M: *Schizophrenia: A Practical Primer*. Aug 1312–1313
Roose SP. Identifying and treating cognitive impairments in elderly patients. Dec e31
Roose SP see Rutherford BR
Rosa MA see Rosa MO
Rosa MO, Gattaz WF, Rosa MA, Rumi DO, Tavares H, Myczkowski M, Sartorelli MC, Rigonatti SP, Elkis H, Cabral SB, Teixeira MJ, Marcolin MA. Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. Oct 1528–1532
Rosati MJ see Martin KA
Rosenbaum JF see Cusin C
Rosenberg J see Salzman C

Rosenheck RA. Aripiprazole and perphenazine: no difference [letter with reply]. Nov 1812–1814
Rosenheck RA, Lieberman JA. Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia. Feb e05
Rosenthal NR see Tucker P
Ross DE see Hettema JM
Ross R see Weiden PJ
Ross-Degnan D see Bambauer KZ
Roth T. Introduction. Narcolepsy and excessive daytime sleepiness: from the bench to the bedside. Suppl 13, 4
Roth T. Introduction. Understanding neuronal pathways: novel targets for the management of insomnia. Suppl 5, 4–5
Roth T. Narcolepsy: treatment issues. Suppl 13, 16–19
Roth T. Physiologic basis for the evolution of pharmacotherapy for insomnia. Suppl 5, 13–18
Rothschild AJ see Andreescu C; Keller MB; Kocsis JH
Rouillon F see Friedman S
Roye GD see Zimmerman M
Ruiz P. Review of Kranzler HR, Ciraulo DA (eds): *Clinical Manual of Addiction Psychopharmacology*. Jan 174
Rumi DO see Rosa MO
Rummans TA see Rasmussen KG
Rush AJ. Limitations in efficacy of antidepressant monotherapy. Suppl 10, 8–10
Rush AJ. Varied clinical presentations of major depressive disorder. Suppl 8, 4–10
Rush AJ see Davis LL; Moore HK; Morris DW
Russell JM see Endicott J
Rutherford BR, Aizaga K, Sneed J, Roose SP. Survey of psychiatry residents' informed consent practices. Apr 558–565
Rymaszewska J see Kallert TW
Saarni SI see Suvisaari JM
Sachs GS, Gaulin BD, Gutierrez-Esteinou R, McQuade RD, Pikalov A III, Pultz JA, Sanchez R, Marcus RN, Crandall DT. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. Sept 1377–1383
Sachs GS see Truman CJ
Sack DA see Tran-Johnson TK
Saddichha S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. Nov 1793–1798
Sajatovic M see Madhusoodanan S
Salize HJ see Gaebel W
Salminen JK see Korkeila J
Salokangas RKR see Korkeila J
Salomon RM. Review of Levenson JL (ed): *The American Psychiatric Publishing Textbook of Psychosomatic Medicine*. Dec 1990
Salomon RM. Review of Taylor MA, Fink M: *Melancholia: The Diagnosis, Pathophysiology, and Treatment of Depressive Illness*. June 978
Salvati L see Tundo A
Salzman C, Rosenberg J, Feldman JJ. Schizophrenia symptoms remain stable during decreases from 2 antipsychotics to aripiprazole [letter]. June 970
Sampson SM see Rasmussen KG
San L see Arranz B
Sanchez R see Kane JM; Keck PE Jr; Sachs GS
Sanchez-Moreno J see Romero S
Sanger TM see Thase ME
Sanislow CA see Grilo CM; Markowitz JC; Skodol AE
Santonastaso P see Favaro A
Sareen J see Cox BJ
Sarles RM. Review of Petti TA, Salguero C (eds): *Community Child and Adolescent Psychiatry: A Manual of Clinical Practice and Consultation*. Feb 339–340
Sartorelli MC see Rosa MO
Sasan A see Marano CM
Sasayama D see Sugiyama N
Schacht A see Karow A
Schaffer A, Cairney J, Veldhuizen S, Cheung A, Levitt A. Comparison of antidepressant use between subjects with bipolar disorder and major depressive disorder with or without comorbid anxiety. Nov 1785–1792
Scharfetter C see Stassen HH
Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. Suppl 8, 26–34
Schatzberg AF see Keller MB; Kocsis JH; Michelson D
Schimmelmann BG see Karow A
Schlösser R see Gaebel W
Schmidt LG see Gaebel W
Schmitt A see Gaebel W
Schneider F see Gaebel W
Schnyer RN, Chambers AS, Hitt SK, Moreno FA, Manber R, Allen JJB. Reply to Yeung A: Acupuncture for major depressive disorder: has its efficacy been disproved? [letter] Oct 1617–1618
Schooler NR see Moore TA
Schruers KRJ see Cosci F
Schulz SC see Kahn RS
Schürer F see Körtner K
Schützwohl M see Kallert TW
Schwartz K see Khan A
Scordo MG see Melkersson KI
Segal ZV see Carney CE
Seitz DP, Gill SS, van Zyl LT. Antipsychotics in the treatment of delirium: a systematic review. Jan 11–21
Sela B-A see Lerner V
Sepehry AA, Potvin S, Élie R, Stip E. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. Apr 604–610
Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. Suppl 3, 14–18
Sernyak MJ see Newcomer JW
Serretti A see Souery D
Shah MR see Cornblatt BA
Shaw JJ see Flynn SM
Shea MT see Skodol AE
Shear MK see McHugh RK
Shelton RC. Augmentation strategies to increase antidepressant efficacy. Suppl 10, 18–22
Shelton RC. Reply to Lusicic A: Sertraline versus venlafaxine XR in major depressive disorder [letter with reply]. Oct 1618–1619
Shelton RC see Davis LL; Dunner DL; Keller MB; Kocsis JH; Papakostas GI
Shon SP see Moore TA
Sichieri R see Claudino AM
Sikes CR see Friedman MJ
Silkey BS see Harvey AT
Sim K, Chan YH, Chong SA, Siris SG. A 24-month prospective outcome study of first-episode schizophrenia and schizoaffective disorder within an early psychosis intervention program. Sept 1368–1376
Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unützer J. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. Aug 1237–1245
Simonsen C see Birkenaes AB
Simpson WB see van der Kolk BA
Singh D, Goodkin K. Choice of antipsychotic in HIV-infected patients [ASCP Corner]. Mar 479–480
Singh D, Goodkin K. Psychopharmacologic treatment response of HIV-infected patients to antipsychotic medications [ASCP Corner]. Apr 631–632
Singh NM see Kumar PNS
Siris SG see Sim K
Siu CO see Loebel AD
Sjöstedt G see Fazel S
Skale TG, Jain R. Practical strategies for assessing and stabilizing bipolar patients in urgent situations. Oct e23
Skodol AE, Bender DS, Pagano ME, Shea MT, Yen S, Sanislow CA, Grilo CM, Daversa MT, Stout RL, Zanarini MC, McGlashan TH, Gunderson JG. Positive childhood experiences: resilience and recovery from personality disorder in early adulthood. July 1102–1108

Skodol AE see Grilo CM; Markowitz JC
Skogvoll E see Castberg I
Slattery MJ see Infante M
Slooff CJ see Wunderink L
Smith CW see Cornblatt BA
Smith J see Papakostas GI
Smith S see Howes OD
Smits JAJ see Otto MW
Sneed J see Rutherford BR
Soares CN, Taylor V. Effects and management of the menopausal transition in women with depression and bipolar disorder. Suppl 9, 16–21
Soares CN see Joffe H
Soczynska JK see McIntyre RS
Soekadar S see Marano CM
Sofia-Gabrion CK, Yahia YA, Holzer L. Olanzapine and blepharoclonus [letter]. Sept 1443–1444
Soldato M see Onder G
Somley BL see Joffe H
Sommer IE see Aleman A
Soni P see Reimherr FW
Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J, for the Group for the Study of Resistant Depression (GSRD). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. July 1062–1070
Soumerai SB see Bambauer KZ
Sparshatt A see Atkinson JM
Spencer TJ see Monuteaux MC
Spielman L see Difede J
Spigset O see Castberg I
Spinazzola J see van der Kolk BA
Spivey JM see Brashear HR
Spurling RD, Lamberti JS, Olsen D, Tu X, Tang W. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. Mar 406–409
Sribney W see Fortuna LR
Stahl SM. Reply to Brophy MH: Different mechanism to understand activation/sedation side effects of ziprasidone [letter]. June 974–976
Stajic M see Leon AC
Stan VA see Ghaemi SN
Stanford KE see DelBello MP
Stang PE see Fishman PA
Stanley B see Wilson ST
Stansbrey RJ see Findling RL
Stárková-Kališová L see Kallert TW
Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? evidence from 2848 patients. Aug 1195–1205
Stauffer VL see Karagianis J
Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B. Reply to Mattes JA: More on placebo response [letter]. Dec 1984–1985
Steiner H see Plattner B
Stelzig-Schoeler R see Aichhorn W
Stening G see Brecher M
Stephan DA see Coon KD
Stern C see Khan A
Stewart JW. Treating depression with atypical features. Suppl 3, 25–29
Stewart JW, Thase ME. Treating DSM-IV depression with atypical features. Apr e10
Stewart R see Moran P
Stip E see Sepehry AA
Stoddard FJ Jr. Review of Yudofsky SC: *Fatal Flaws: Navigating Destructive Relationships With People With Disorders of Personality and Character.* Feb 341–342
STOP-PD Study Group see Andreescu C
Stout RL see Grilo CM; Skodol AE
Stowe ZN. Use of mood stabilizers during breastfeeding. Suppl 9, 22–28
Strakowski SM see DelBello MP
Strong RE see Reimherr FW
Stroup TS see Moore TA
Study 132 Investigators see Kahn RS
Stuppaeck C see Aichhorn W
Su K-P see Huang C-L; Lin P-Y
Su T-P see Bai YM
Su T-PT see Chan H-Y
Subramaniam M see Mahendran R
Sugiyama N, Sasayama D, Amano N. Remarkable antidepressant augmentation effect of raloxifene, a selective estrogen receptor modulator, in a partial responder to fluvoxamine: a case report [letter]. Apr 636–637
Sundet K see Birkenaes AB
Suominen KS see Arvilommi P
Surman CBH, Randall ET, Biederman J. Reply to Cortese S: Attention-deficit/hyperactivity disorder, binge eating, and obesity [letter]. June 976–977
Suvisaari JM, Saarni SI, Perälä J, Suvisaari JVJ, Härkänen T, Lönnqvist J, Reunanen A. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. July 1045–1055
Suvisaari JVJ see Suvisaari JM
Suzuki K see Kaneita Y
Svensson O see Kahn RS
Swanink R see Berman RM
Sweitzer DE, Lazarus A, Brecher M. Reply to Gharabawi GM: Discussion of 2 double-blind studies comparing risperidone and quetiapine in patients with schizophrenia [letter]. Feb 333–334
Swindle RW see Endicott J
Sysko R, Walsh BT. Systematic review of placebo response in studies of bipolar mania. Aug 1213–1217
Sytema S see Wunderink L
Szarek BL see Goethe JW
Szegedi A see Stassen HH
Szilagyi KA see Manwani SG
Taanila A see Riala K
Tai JY see Cornblatt BA
Takahashi E see Yamamoto K
Tan YL see Zhang XY
Tang W see Spurling RD
Tanihata T see Kaneita Y
Tardiff K see Leon AC
Tariot PN, Reiman EM. In memoriam: Leon J. Thal, M.D., 1944–2007. Apr 501
Tarrier N see Drake RJ
Tavares H see Rosa MO
Taylor DM see Atkinson JM
Taylor V see Soares CN
Teixeira MJ see Rosa MO
Teng P-R see Cheng ATA
Thase ME. Introduction: new directions in the treatment of atypical depression. Suppl 3, 4–7
Thase ME. Recognition and diagnosis of atypical depression. Suppl 8, 11–16
Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, Watson SB, Dubé S. Randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. Feb 224–236
Thase ME see Blier P; Davidson JRT; Keller MB; Kocsis JH; Papakostas GI; Parker GB; Rapaport MH; Stewart JW; Truman CJ
The SSL see Plattner B
Thienhaus OJ. Review of Dulcan MK, Wiener JM (eds): *Essentials of Child and Adolescent Psychiatry.* July 1151–1152
Thompson J see Tucker P
Thongy T see Zimmerman M
Tillman R, Geller B. Diagnostic characteristics of child bipolar I disorder: does the "Treatment of Early Age Mania (TEAM)" sample generalize? Feb 307–314
Timonen M see Riala K
Tomba E see Fabbri S
Tondo L see Guzzetta F
Torres LR, Zayas LH, Cabassa LJ, Pérez MC. Diagnosing co-occurring substance-related disorders: agreement between SCID, Hispanic clinicians, and non-Hispanic clinicians. Nov 1655–1662
Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. Jan 111–119
Trautman RP see Tucker P
Treuer T see Karagianis J
Trevino JJ. Review of Hermann RC: *Improving Mental Healthcare: A Guide to Measure-Based Quality Improvement.* Apr 642–643

Tricco AC see Katzman MA
Trivedi MH, Clayton AH, Frank E. Treating anxiety complicated by comorbid medical illness or anxiety. Jan e01
Trivedi MH see Davis LL; Keller MB; Kocsis JH; Moore HK; Morris DW; Otto MW
Truman CJ, Goldberg JF, Ghaemi SN, Baldassano CF, Wisniewski SR, Dennehy EB, Thase ME, Sachs GS. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Oct 1472–1479
Tu X see Spurling RD
Tucker P, Trautman RP, Wyatt DB, Thompson J, Wu S-C, Capece JA, Rosenthal NR. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Feb 201–206
Tucker VL see Papakostas GI
Tundo A, Salvati L, Busto G, Di Spigno D, Falcini R. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study. Oct 1552–1556
Turecki G see McGirr A
Tylee A, Walters P. Underrecognition of anxiety and mood disorders in primary care: why does the problem exist and what can be done? Suppl 2, 27–30
Tylee A see Nutt DJ
Tzanis E see Ferguson JM
Uguz F, Akman C, Kaya N, Cilli AS. Postpartum-onset obsessive-compulsive disorder: incidence, clinical features, and related factors. Jan 132–138
Unützer J see Simon GE
Upadhyaya HP. Managing ADHD in the presence of comorbid substance use disorder. June e15
Upadhyaya HP. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder. Suppl 11, 23–30
Upadhyaya HP see Faraone SV; Levin FR; Wilens TE
Valenstein M see Kilbourne AM
Valtonen H see Arvilommi P
Van Ameringen M, Mancini C, Oakman J, Walker J, Kjernisted K, Chokka P, Johnston D, Bennett M, Patterson B. Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. Feb 288–295
van Balkom AJLM see de Jonge JL; Mol AJJ
van de Lisdonk EH see Mol AJJ
van der Kolk BA, Spinazzola J, Blaustein ME, Hopper JW, Hopper EK, Korn DL, Simpson WB. Randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Jan 37–46
Van der Velden PG, Grievink L, Olff M, Gersons BPR, Kleber RJ. Smoking as a risk factor for mental health disturbances after a disaster: a prospective comparative study. Jan 87–92
van Elst LT see Philipsen A
Van Nieuwerburgh F see Denys D
van Wattum PJ. Review of Cheng K, Myers KM (eds): *Child and Adolescent Psychiatry: The Essentials*. Aug 1312
van Winkel R, De Hert M. Reply to Cohen D: Applicability of the oral glucose tolerance test in assessing prevalence and incidence of diabetes mellitus in schizophrenia [letter]. Aug 1307–1309
van Zyl LT see Seitz DP
Vaskinn A see Birkenaes AB
Vazquez-Barquero JL see Perez-Iglesias R
Veldhuizen S see Schaffer A
Vemulapalli UR see Marano CM
Vemuri MP, Rasgon NL. Case of olanzapine-induced gestational diabetes mellitus in the absence of weight gain [letter]. Dec 1989
Venkatasubramanian G see Behere RV; Rao NP
Victor MM see Reinhardt MC
Vieta E see González-Pinto A; Mur M; Romero S
Viguera AC, Koukopoulos A, Muzina DJ, Baldessarini RJ. Teratogenicity and anticonvulsants: lessons from neurology to psychiatry. Suppl 9, 29–33. Correction, Dec 1989
Viguera AC see Joffe H; Pearson KH
Vink D see Kok RM
Virtanen EM see Honkonen TI
Volz A see Bäuml J
von Wilmsdorff M see Gaebel W
Voshaar RCO see Mol AJJ
Vreeland B. Bridging the gap between mental and physical health: a multidisciplinary approach. Suppl 3, 26–33
Vreeland B. Treatment decisions in major mental illness: weighing the outcomes. Suppl 12, 5–11
Vreeland B see Ganguli R
Wada K see Kaneita Y
Wade D, Harrigan S, McGorry PD, Burgess PM, Whelan G. Impact of severity of substance use disorder on symptomatic and functional outcome in young individuals with first-episode psychosis. May 767–774
Wagner HR II see Gadde KM
Wagner M see Buch S
Wagner T see Karow A
Walker DG see Coon KD
Walker J see Van Ameringen M
Walker P see Caroff SN
Walsh BT see Sysko R
Walters P see Tylee A
Wang H-R see Yoo HK
Wang L see Robertson B
Wang Y-C see Bai YM
Wasylink S see Coric V
Watson SB see Thase ME
Webster JA see Coon KD
Wedervang-Jensen T see Kørner A
Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. Suppl 1, 12–19
Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. Suppl 3, 34–39
Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. Suppl 14, 14–19
Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. Suppl 6, 14–23
Weiden PJ, Miller AL, Lambert TJ, Buckley PF. Art and science of switching antipsychotic medications, part 2. Jan e02
Weiden PJ, Newcomer JW. Evidence of switching antipsychotic therapy to improve metabolic disturbances. May e13
Weiden PJ, Preskorn SH, Fahnestock PA, Carpenter D, Ross R, Docherty JP. Translating the Psychopharmacology of Antipsychotics to Individualized Treatment for Severe Mental Illness: A Roadmap. Suppl 7, 3–46
Weinstein DD. Review of Grant JE, Potenza MN (eds): *Pathological Gambling: A Clinical Guide to Treatment*. May 807
Weiss M see Jain U
Weiss RD see Manwani SG
Welge JA see McElroy SL
West B see Marder SR
Westenberg HGM see Denys D
Wetherell JL see Meeks TW
Wexler TL see Miller KK
Wheeler MJ see Howes OD
Whelan G see Wade D
Whicker NE see Compton MT
Whitmyer VG, Dunner DL, Kornstein SG, Meyers AL, Mallinckrodt CH, Wohlreich MM, Gonzales JS, Greist JH. Comparison of initial duloxetine dosing strategies in patients with major depressive disorder. Dec 1921–1930
Whitsel RM see DelBello MP
Whyte EM see Andreescu C
Widen JH see Morken G
Wiersma D see Wunderink L

Wilens TE. Nature of the relationship between attention-deficit/hyperactivity disorder and substance use. Suppl 11, 4–8
Wilens TE, Upadhyaya HP. Impact of substance use disorder on ADHD and its treatment. Aug e20
Wilens TE see Faraone SV
Wilkins K see McIntyre RS
Williams DW see Michelson D
Williams ED see Reimherr FW
Williams KA see Grant JE
Williams RP see Plattner B
Williford RB see Davis LL
Wilson AM see Monuteaux MC
Wilson ST, Stanley B, Oquendo MA, Goldberg P, Zalsman G, Mann JJ. Comparing impulsiveness, hostility, and depression in borderline personality disorder and bipolar II disorder. Oct 1533–1539
Wingo AP, Ghaemi SN. Systematic review of rates and diagnostic validity of comorbid adult attention-deficit/hyperactivity disorder and bipolar disorder. Nov 1776–1784
Wirshing DA see Pierre JM
Wirshing WC see Pierre JM
Wisniewski SR see Davis LL; Morris DW; Truman CJ
Witztum E see Lerner V
Wohlreich MM see Whitmyer VG
Wölwer W see Gaebel W
Wood SJ see Berger GE
Woods SW see McHugh RK
Woolley SB see Goethe JW
Worthington JJ see Kinrys G
Wu B see Bai YM
Wu GY see Zhang XY
Wu S-C see Tucker P
Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. May 654–661
Wyatt DB see Tucker P
Wygant L see Kinrys G
Xing Q-H see Xu M-Q
Xu F see Xu M-Q
Xu M-Q, Xing Q-H, Zheng Y-L, Li S, Gao J-J, He G, Guo T-W, Feng G-Y, Xu F, He L. Association of *AKT1* gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. Sept 1358–1367
Yager J see Arnold KK
Yahia YA see Sofia-Gabrion CK
Yamamoto K, Fukuda M, Nogawa A, Takahashi E, Miyaoka H. Decreased lipoprotein lipase as a risk factor for atypical neuroleptic–induced hypertriglyceridemia [letter]. May 802
Yan B see Keller MB; Kocsis JH
Yang W-S see Bai YM
Yang Y see Clayton AH
Yen AMF see Cheng ATA
Yen S see Skodol AE
Yeung A, Mischoulon D, Alpert J, Ma Y, Fava M. Acupuncture for major depressive disorder: has its efficacy been disproved? [letter with reply] Oct 1617–1618
Yeung PP see DeMartinis NA; Liebowitz MR
Yonish GM see Gadde KM
Yoo HK, Choi S-H, Park S, Wang H-R, Hong J-P, Kim C-Y. Open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. July 1088–1093
Young AH. Treatment of bipolar disorder with antipsychotic medication: issues shared with schizophrenia. Suppl 6, 24–25
Young D see Zimmerman M
Youngstrom EA see Duax JM; Findling RL
Yuen H see Berger GE
Zablotsky B see Ghaemi SN; Manwani SG
Zajecka JM. Augmentation strategies to increase antidepressant tolerability. Suppl 10, 23–27
Zajecka JM see Blier P; Keller MB; Kocsis JH
Zalsman G see Wilson ST
Zanarini MC see Skodol AE
Zayas LH, Cabassa LJ, Perez MC, Cavazos-Rehg PA. Using interpreters in diagnostic research and practice: pilot results and recommendations. June 924–928
Zayas LH see Torres LR
Zha AM see Miller KK
Zhang F see Bambauer KZ
Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, Kosten TA, Kosten TR. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. May 754–760
Zhao F see Dunayevich E
Zheng Y-L see Xu M-Q
Zhou DF see Zhang XY
Zhu Y see Gharabawi GM
Zierhut KC, Richter MM, Renner TJ, Fallgatter AJ. Occurrence of reversible bilateral scotoma 1 hour after single-pulse transcranial magnetic stimulation: a case report [letter]. Mar 488–489
Zimmerman M, Francione-Witt C, Chelminski I, Young D, Boerescu D, Attiullah N, Pohl D, Roye GD, Harrington DT. Presurgical psychiatric evaluations of candidates for bariatric surgery, part 1: reliability and reasons for and frequency of exclusion. Oct 1557–1562
Zimmerman M, Thongy T. How often do SSRIs and other new-generation antidepressants lose their effect during continuation treatment? evidence suggesting the rate of true tachyphylaxis during continuation treatment is low. Aug 1271–1276
Zismann VL see Coon KD
Zitman FG see Mol AJJ
Zito JM. Pharmacoepidemiology: recent findings and challenges for child and adolescent psychopharmacology [ASCP Corner]. June 966–967
Zohar J see Souery D

visit *The Journal of Clinical Psychiatry* @
www.psychiatrist.com